Navigation Links
New Weight-Loss Drug Shows Promise in Trial
Date:5/11/2012

THURSDAY, May 10 (HealthDay News) -- A new weight-loss drug that is awaiting approval from the U.S. Food and Drug Administration showed promising results in a recent international trial, researchers report.

Volunteers who took Qnexa, a combination of the drugs phentermine and topiramate, experienced substantial weight loss, even if they had many weight-related health problems, the study found. The findings were reported this week during the European Congress on Obesity in Lyon, France.

The 56-week clinical trial included 994 patients who took a placebo, 498 who took a medium dose of Qnexa, and 995 who took a high dose of the drug.

Patients who took Qnexa had significantly greater weight loss than those who took the placebo, researchers Stephan Rossner, of the Karolinska Institute in Stockholm, Sweden, and Arya Sharma, of the University of Alberta in Edmonton, Canada, said in a news release from the European Congress on Obesity.

Earlier this year, a U.S. Food and Drug Administration advisory panel recommended that the agency approve the drug for the treatment of obesity. The FDA is scheduled to announce its decision July 17. European officials are expected to make a decision about the combination treatment by mid-summer.

Meanwhile, an FDA advisory panel on Thursday gave its blessing to yet another new weight-loss drug, locaserin, despite lingering concerns about possible cardiac side effects, the Associated Press reported.

Although effective at reducing weight, Qnexa, manufactured by Vivus Inc., was denied approval in 2010 because of its potential side effects. Before making its decision in February, the FDA advisory panel reviewed two years of data on the drug; when advisers previously voted on Qnexa, only one year's worth of follow-up data was available.

Qnexa combines the appetite suppressant phentermine (brand name Adipex-P) and the anti-seizure/migraine medication topiramate (brand name Topamax). Phentermine once was prescribed widely as the "phen" part of the fen-phen weight-loss drug, which was withdrawn from the market in 1997 after its use was linked to both high blood pressure in the lungs and heart valve disease. The problems were related to the "fen," or fenfluramine, part of the combination, not the phentermine, scientists said.

No new weight-loss drug has been approved in the United States in the past 13 years, according to published reports. As it stands, Xenical is the only FDA-approved drug specifically for long-term use -- up to a year -- for weight loss. Xenical is sold over the counter as Alli. Other drugs, however, may be used off-label to promote weight loss.

Last April, a study funded by Vivus found that obese patients taking Qnexa lost an average of 22 pounds over a year, while also lowering their blood pressure and cholesterol levels.

Dr. Louis Aronne, founder and director of the Comprehensive Weight Control Program at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, was cautiously optimistic that Vivus did a good job responding to FDA safety concerns, and that the FDA will give the drug its nod of approval -- with some caveats. Aronne was not involved in the trials but has been an adviser to Vivus and other companies developing weight-loss medications.

Vivus has reported that Qnexa may increase the risk of cleft lip in babies of women who use the drug while pregnant. Aronne said the birth defect concern could be addressed through education on who should and should not use the drug.

"We have learned our lessons with weight-loss drugs," he said. "They need to be used in the right people under the right circumstances." The heart risks need to be weighed against reductions in heart disease risk factors that come with weight loss, he explained.

Qnexa is no riskier than bariatric surgery, Aronne said, but it can be distributed more widely. He hopes for a compromise that allows the new compound to be prescribed but not misused.

"Once new medications are approved, local medical boards will need to enforce rules and make sure these medications are prescribed appropriately to the right candidates," he said. "We don't want to open up pill mills."

Dr. Scott Kahan, an obesity expert at Johns Hopkins University in Baltimore and director of the National Center for Weight and Wellness in Washington, D.C., agreed that Qnexa looks promising.

"The weight-loss effects are striking and approaching the amount of weight loss over two years that we get with bariatric surgery," Kahan said. "This is really impressive."

More information

Learn more about weight-loss medications at the U.S. National Institutes of Health.

-- Robert Preidt

SOURCES: Louis Aronne, M.D., founder and director, Comprehensive Weight Control Program, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York City; Scott Kahn, M.D., associate director, Johns Hopkins Weight Management Center, Baltimore, and director, National Center for Weight and Wellness, Washington, D.C.; European Congress on Obesity, news release, May 12, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
2. Weight-Loss Surgeries May Beat Standard Treatments for Diabetes
3. Weight-Loss Surgery Seems Safe for Kidney Disease Patients
4. Mid-morning snacking may sabotage weight-loss efforts
5. Weighing Weight-Loss Programs
6. Weight Watchers Produces Bigger Losers Than Standard Weight-Loss Care
7. U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall
8. Weight-Loss Surgery Gains More Practitioners
9. Rigorous Exercise May Boost Benefits of Weight-Loss Surgery
10. Weight-loss surgery cost-effective for all obese
11. Weight-Loss Surgery Helps Less Obese Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Weight-Loss Drug Shows Promise in Trial
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 ... know what causes its kissing cousin – upper back pain. But this equally vexing condition ... treatment options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic ...
(Date:8/16/2017)... ... August 16, 2017 , ... “Mom, God's Got This: Jamie's Story” is the creation ... with the Lord and has an insatiable appetite for God’s Word. , “I froze between ... free gifts retrieved from packages of oatmeal. I have one to this day on proud ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... 15, 2017 , ... Horizon Goodwill is honored to receive ... overwhelmed with gratitude for the very generous donation from BB&T. Our mission is ... get a job and keep it. This donation will go a long way ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... to announce the 19th Annual V Foundation Wine Celebration raised nearly $9 million ... more than $7 million in “Fund-A-Need” donations to support the study of BRCA ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... and Gulf Coast Regional Blood Center to host a blood ... Law family has had 3 members that needed blood products ... is partnering with Gulf Coast Regional Blood Center of ... supplies are running low. Gulf Coast Regional Blood Center,s inventory is ... is why the blood center reached out to Mostyn Law ...
(Date:8/15/2017)... 15, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan residents. Naloxone is available ... retail pharmacy, G-3320 Beecher Road. ... and Drug Administration, is intended to block or reverse ... and loss of consciousness. The medication is often carried ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator ... rumored to be in the beginning stages of an IPO. ... on epilepsy medications with the average cost of a prescription epilepsy drug ... ... Another staggering figure is the fact ...
Breaking Medicine Technology: